Advisor Group Holdings, Inc. Salarius Pharmaceuticals, Inc. Transaction History

Advisor Group Holdings, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.17 - $41.34 $0 - $165	-4 Reduced 0.01%	34,700 $6,000
Q1 2022 May 04, 2022	BUY	$0.34 - $0.54 $4,035 - $6,409	11,870 Added 51.98%	34,704 $14,000
Q3 2021 Nov 05, 2021	BUY	$0.8 - $1.15 $104 - $149	130 Added 0.57%	22,834 $23,000
Q1 2021 May 13, 2021	BUY	$1.0 - $3.0 $8,476 - $25,428	8,476 Added 59.57%	22,704 $34,000
Q4 2020 Feb 10, 2021	BUY	$0.65 - $1.34 $7,495 - $15,452	11,532 Added 427.74%	14,228 $13,000
Q3 2020 Nov 12, 2020	BUY	$0.77 - $1.52 $1,345 - $2,656	1,748 Added 184.39%	2,696 $2,000
Q2 2020 Aug 14, 2020	SELL	$0.6 - $1.82 $453 - $1,375	-756 Reduced 44.37%	948 $1,000
Q1 2020 May 18, 2020	BUY	$0.56 - $3.82 $954 - $6,509	1,704 New	1,704 $1,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $3.37M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.